Abstract
Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have